MedTrace Logo

Hyper-CVAD Treatment in Lymphoblastic Lymphoma

NCT01813344 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2013-03-19

No results posted yet for this study

Summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Conditions

  • Lymphoblastic Lymphoma

Sponsors & Collaborators

  • Ajou University School of Medicine

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01813344 on ClinicalTrials.gov